s3304

S-3304 is a n orally-agent agent with potential antineoplastic activity. S-3304 inhibits matrix metalloproteinases (MMPs), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.

1. Tetrahydrocoptisine (STYLOPINE) has effective effects in suppressing inflammation. 2. Tetrahydrocoptisine possesses a protective effect on LPS-induced ALI through inhibiting of NF-κB signaling pathways, which may involve the inhibition of pulmonary inflammatory process. 3. Tetrahydrocoptisine has gastroprotective activity, is attributed to reducing NO production and adjusting the pro-inflammatory cytokine, inhibited neutrophil accumulation and NF-κB expression. 4. Tetrahydrocoptisine is an active anti-inflammatory constituent by inhibition of TNF-α, IL-6 and NO production possibly via down-regulation of NF-κB activation, phospho-ERK1 2 and phospho-p38MAPK signal pathways.

S 3304 is a novel matrix metalloproteinase inhibitor, specifically targeting MMP-2 and MMP-9.

MMI-166 is a selective matrix metalloproteinase (MMP) inhibitor that prevents tumor invasion and metastasis by downregulating the activity of MMP-2 and MMP-9.